ATXN2 and Huntington disease: Therapeutic strategies that reduce specifically polyQ-expanded protein levels are currently being applied to slow or stop disease progression in polyQ diseases like SCA1 [66, 67], SCA2 [68], HD [69, 70], and SCA3 [71–74].